Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial)
- DOI
- 10.1016/j.clcc.2026.09.004
- Published
- 2026-10
- Container
- Clinical Colorectal Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.clcc.2026.09.004,
title = {Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial)},
author = {Alessandra Pia D’Agata and Gloria Pellizzari and Giulia Martini and Michele Ghidini and Stefania Napolitano and Maria Giulia Zampino and Nicola Fazio and Filippo Pietrantonio and Paolo Manca and Andrea Sartore-Bianchi and Alberto Puccini and Salvatore Corallo and Alberto Zaniboni and Giulia Piacentini and Francesca Bergamo and Fabio Gelsomino and Luisa Foltran and Alessandro Passardi and Chiara Cremolini and Lorenzo Antonuzzo and Giampaolo Tortora and Rossana Berardi and Antonio Avallone and Michele Orditura and Gianluca Arrichiello and Giuseppe Santabarbara and Antonio Febbraro and Tiziana Pia Latiano and Claudio Lotesoriere and Iaia Maria Laura and Pierosandro Tagliaferri and Alfredo Colombo and Marco Messina and Alessio Cogoni and Salvatore Pisconti and Roberto Bordonaro and Fortunato Ciardiello and Davide Ciardiello},
year = {2026},
journal = {Clinical Colorectal Cancer},
doi = {10.1016/j.clcc.2026.09.004},
url = {https://doi.org/10.1016/j.clcc.2026.09.004}
}RIS
TY - JOUR TI - Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial) AU - Alessandra Pia D’Agata AU - Gloria Pellizzari AU - Giulia Martini AU - Michele Ghidini AU - Stefania Napolitano AU - Maria Giulia Zampino AU - Nicola Fazio AU - Filippo Pietrantonio AU - Paolo Manca AU - Andrea Sartore-Bianchi AU - Alberto Puccini AU - Salvatore Corallo AU - Alberto Zaniboni AU - Giulia Piacentini AU - Francesca Bergamo AU - Fabio Gelsomino AU - Luisa Foltran AU - Alessandro Passardi AU - Chiara Cremolini AU - Lorenzo Antonuzzo AU - Giampaolo Tortora AU - Rossana Berardi AU - Antonio Avallone AU - Michele Orditura AU - Gianluca Arrichiello AU - Giuseppe Santabarbara AU - Antonio Febbraro AU - Tiziana Pia Latiano AU - Claudio Lotesoriere AU - Iaia Maria Laura AU - Pierosandro Tagliaferri AU - Alfredo Colombo AU - Marco Messina AU - Alessio Cogoni AU - Salvatore Pisconti AU - Roberto Bordonaro AU - Fortunato Ciardiello AU - Davide Ciardiello PY - 2026 JO - Clinical Colorectal Cancer DO - 10.1016/j.clcc.2026.09.004 UR - https://doi.org/10.1016/j.clcc.2026.09.004 ER -
APA
D’Agata, A. P., Pellizzari, G., Martini, G., Ghidini, M., Napolitano, S., Zampino, M. G., Fazio, N., Pietrantonio, F., Manca, P., Sartore-Bianchi, A., Puccini, A., Corallo, S., Zaniboni, A., Piacentini, G., Bergamo, F., Gelsomino, F., Foltran, L., Passardi, A., Cremolini, C., Antonuzzo, L., Tortora, G., Berardi, R., Avallone, A., Orditura, M., Arrichiello, G., Santabarbara, G., Febbraro, A., Latiano, T. P., Lotesoriere, C., Laura, I. M., Tagliaferri, P., Colombo, A., Messina, M., Cogoni, A., Pisconti, S., Bordonaro, R., Ciardiello, F., & Ciardiello, D. (2026). Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial). Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.09.004
Source records
- crossref · retrieved 2026-11-03T15:11:12.488Z